Abstract:Albendazole is loaded into Santa Barbara Amorphous‐15 (SBA‐15) using a Box‐Behnken design to study the effects of key loading factors on drug loading (DL%) and dissolution efficiency (DE%). The amount of SBA‐15 is found to have the greatest impact on both DL% and DE%. Most samples preserve similar dissolution profiles after 12 months, indicating good stability of the drug in the carrier over time. Over 70% of pharmaceutical compounds face the challenge of poor water solubility, which impacts on their bioavailability. This study focuses on the use of Santa Barbara Amorphous‐15 (SBA‐15) mesoporous silica material as carrier, which is synthesized and characterized to address this limitation. Albendazole (ABZ), an antiparasitic agent with low water solubility, serves as model drug. A Box‐Behnken design (BBD) is used to investigate the impact of immersion method loading factors (temperature: 25–50 °C, time: 24–72 h, and SBA‐15 amount: 83.2–252.0 mg) on drug loading percentage (DL%) and dissolution efficiency (DE%). The ABZ loading is confirmed by elemental analysis and Fourier transform infrared spectroscopy. Stability tests are performed, comparing drug dissolution profiles and X‐ray diffraction patterns immediately after loading and after 12 months of storage at 25 °C and 60% relative humidity (RH%). DL% varies between 18% and 36% (w/w), showing that the amount of SBA‐15 is the most significant factor on DL%. The lowest SBA‐15 amount yielded the highest DL%. Regarding DE%, all the design samples exhibit higher values than pure ABZ, with the amount of SBA‐15 being the primary influencing factor. Several samples from the BBD show high DE% (>70%) corresponding to high DL% values. After 12 months, most samples maintain similar dissolution profiles, demonstrating the good stability of the drug in the carrier over time. This study provides valuable insights into optimizing the loading process to enhance ABZ solubility and long‐term stability using mesoporous SBA‐15.

Albendazole Solid Dispersions Prepared Using Peg6000 And Poloxamer188: Formulation, Characterization Andin Vivoevaluation

Enhanced Oral Bioavailability and Anti-Echinococcosis Efficacy of Albendazole Achieved by Optimizing the "spring" and "Parachute"

Improved Dissolution of Albendazole from High Drug Loaded Ternary Solid Dispersion: Formulation and Characterization

Enabling a Novel Solvent Method on Albendazole Solid Dispersion to Improve the in Vivo Bioavailability

Studies on Preparation and Dissolution of Albendazole Solid Dispersions

Improving the Solubility, Stability, and Bioavailability of Albendazole through Synthetic Salts

Development of self-microemulsifying drug delivery system of mebendazole by spray drying technology: Characterization, in vitro and in vivo evaluation

Relevance of Liquid-Liquid Phase Separation of Supersaturated Solution in Oral Absorption of Albendazole from Amorphous Solid Dispersions

Alternative Albendazole Polybutylcyanoacrylate Nanoparticles Preparation, Pharmaceutical Properties and Tissue Distribution in Rats

Enhancing Albendazole Delivery Using Mesoporous Santa Barbara Amorphous‐15: A Box‐Behnken Design Study

Solid Dispersion Tablets of Breviscapine with Polyvinylpyrrolidone K30 for Improved Dissolution and Bioavailability to Commercial Breviscapine Tablets in Beagle Dogs.

In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating.

Preliminary Development of Solid Dispersion for an Insoluble Compound ZL006 by Miniaturized Hot Melt Extrusion

Improvement of Antialveolar Echinococcosis Efficacy of Albendazole by a Novel Nanocrystalline Formulation with Enhanced Oral Bioavailability

Sustained release polymer and surfactant based solid dispersion of andrographolide exhibited improved solubility, dissolution, pharmacokinetics, and pharmacological activity

Studies on Preparation and in Vitro and in Vivo Evaluation of Docetaxel Solid Dispersion

Fenofibrate Solid Dispersion Pellets Prepared by Fluid-Bed Coating: Physical Characterization, Improved Dissolution and Oral Bioavailability in Beagle Dogs

Development of Self-Microemulsifying Drug Delivery Systems for Oral Bioavailability Enhancement of Alpha-Asarone in Beagle Dogs.

Preparation and In Vitro/In Vivo Evaluation of Orally Disintegrating/Modified-Release Praziquantel Tablets

Formulation, Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Glibenclamide for Bioavailability Enhancement in Wistar Rats

Novel Albendazole-Glucan Particles for Enhancing Intestinal Absorption and Improving Hepatic Targeting